Abstract:BACKGROUND AND OBJECTIVES:Photodynamic therapy (PDT) has shown potentially beneficial results in treating port-wine stain, but its benefit-risk profile remains undefined. This study aimed to evaluate the efficacy and safety of PDT conducted with hemoporfin and a 532 nm continuous wave laser to treat port-wine stain clinically.PATIENTS AND METHODS:This randomized clinical trial was conducted in eight hospitals in China. Participants were adolescent and adult patients (age range: 14-65 years old) with port-wine stain. During stage 1 (day 1 to week 8) all patients were randomized at a 3:1 ratio to treatment (532 nm laser irradiation (96-120 J/cm2) with hemoporfin (5mg/kg; PDT-hemoporfin, n = 330)) or placebo groups (irradiation with placebo (PDT-placebo, n = 110)); during stage 2 (week 8 to 16) patients in both groups were offered treatment. Clinician-evaluators, who were blind to the study, classified each case on the following four-level scale according to assessment of before and after standardized pictures of the lesion area: no improvement: <20%; some improvement: 20-59%; great improvement: 60-89%; or nearly completely resolved: ≥90%. The primary efficacy endpoint was proportion of patients achieving at least some improvement at week 8. The secondary efficacy endpoints were proportion of patients achieving nearly completely resolved or at least great improvement at week 8, proportion of patients achieving early completely resolved, at least great improvement, or at least some improvement at week 16, and the corresponding satisfaction of the investigators and the patients (designated as 'excellent', 'good', 'moderate', or 'ineffective') at weeks 8 and 16.RESULTS:Compared to the PDT-placebo group, the PDT-hemoporfin group showed a significantly higher proportion of patients that achieved at least some improvement (89.7% [n = 295; 95% CI, 85.9%-92.5%] vs. 24.5% [n = 27; 95% CI, 17.4%-33.3%]) at week 8 (P < 0.0001) and higher improvements for all secondary efficacy endpoints. Treatment reactions occurred in 99.5% (n = 731; 95% CI, 98.7%-99.8%) of the PDT-hemoporfin treatments (n = 735). Hyperpigmentation occurred in 22.9 per 100 patient-treatments (n = 168; 95% CI, 20.0-26.0) in the PDT-hemoporfin treated patients.CONCLUSIONS:Hemoporfin-mediated PDT is an effective and safe treatment option for adolescent and adult patients with port-wine stain.TRIAL REGISTRATION:Chinese Clinical Trial Registry ChiCTR-TRC-08000213.

Study of pharmacokinetics and cutaneous photosensitization of hemoporfin in healthy volunteers

Gender differences in pharmacokinetics, mass balance and phototoxicity of single-dose intravenous hemoporfin in healthy volunteers

Tolerance and Pharmacokinetics of Single-Dose Intravenous Hemoporfin in Healthy Volunteers

Progress in Porphyrins As a Photosensitizing Drug for Photodynamic Therapy

Efficacy and Safety of Hemoporfin in Photodynamic Therapy for Port-Wine Stain: A Multicenter and Open-Labeled Phase Iia Study

A Dose‐finding Study for Hemoporfin in Photodynamic Therapy for Port‐wine Stain: A Multicenter Randomized Double‐blind Phase IIb Trial

Hemoporfin-mediated photodynamic therapy for the treatment of port-wine stain: A multicenter, retrospective study

Hemoporfin Photodynamic Therapy for Port Wine Stain: A Randomized Controlled Trial

Photocytotoxicity, cellular uptake and subcellular localization of amidinophenylporphyrins as potential photodynamic therapeutic agents: An in vitro cell study

Crosstalk between oxidative stress, autophagy and apoptosis in hemoporfin photodynamic therapy treated human umbilical vein endothelial cells

Metalloporphyrin–indomethacin conjugates as new photosensitizers for photodynamic therapy

Retrospective Analysis of Hemoporfin-mediated Photodynamic Therapy in the Treatment of Naïve Port-Wine Stains

Synthesis, singlet oxygen generation, photocytotoxicity and subcellular localization of azobisporphyrins as potentially photodynamic therapeutic agents in vitro cell study

Determination of a novel photosensitizer sinoporphyrin sodium in human plasma by ultra-performance liquid chromatography–tandem mass spectrometry

Supramolecular organic frameworks improve the safety of clinically used porphyrin photodynamic agents and maintain their antitumor efficacy

Multicentre clinical trial of Hemporfin® photodynamic therapy for port wine stain for their efficacy and safety

Efficacy and safety of hemoporfin photodynamic therapy for port-wine stains in paediatric patients: A retrospective study of 439 cases at a single centre

Porous organic polymer overcomes the post-treatment phototoxicity of photodynamic agents and maintains their antitumor efficiency

Hemoporfin-mediated photodynamic therapy on normal vasculature: implications for phototherapy of port-wine stain birthmarks.

Modified Oxygen Metabolism Toward “sunlight‐friendly” Photodynamic Therapy

Heavy Atom Effect on Water-Soluble Porphyrin Photosensitizers for Photodynamic Therapy